Cargando…
Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination
Anti-CD20 antibodies react with CD20 expressed not only on malignant B cells, but also on normal B cells. It has been reported that patients treated with anti-CD20 antibodies had an insufficient response to two-dose mRNA SARS-CoV-2 vaccination. To investigate the efficacy of a third dose in these pa...
Autores principales: | Funakoshi, Yohei, Yakushijin, Kimikazu, Ohji, Goh, Hojo, Wataru, Sakai, Hironori, Watanabe, Marika, Kitao, Akihito, Miyata, Yoshiharu, Saito, Yasuyuki, Kawamoto, Shinichiro, Yamamoto, Katsuya, Ito, Mitsuhiro, Koyama, Taiji, Imamura, Yoshinori, Kiyota, Naomi, Matsuoka, Hiroshi, Mori, Yasuko, Minami, Hironobu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229139/ https://www.ncbi.nlm.nih.gov/pubmed/35746573 http://dx.doi.org/10.3390/vaccines10060965 |
Ejemplares similares
-
A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients
por: Watanabe, Marika, et al.
Publicado: (2022) -
Increase in Antibody Titers Following Sars-Cov-2 Vaccination Remains Limited for More Than 3 Years after Final Dose of Anti-CD20 Antibody
por: Funakoshi, Yohei, et al.
Publicado: (2021) -
Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody
por: Funakoshi, Yohei, et al.
Publicado: (2022) -
The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation
por: Watanabe, Marika, et al.
Publicado: (2022) -
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer
por: Funakoshi, Yohei, et al.
Publicado: (2022)